Skip to contentL
Ligand Pharmaceuticals Inc
L
LGNDLigand Pharmaceuticals Inc Q3 2018 · 10-Q
Revenue$45.66M$45.66M±0.0% vs Q3 2017 Net Income$67.36M$67.36M±0.0% vs Q3 2017 EPS Diluted$2.80$2.80±0.0% vs Q3 2017 Operating Income$23,362,000+41.6% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin51.2%+15.0 pt vs Q3 2017
Net margin147.5%
ended Sep 30, 2018 · filed Nov 8, 2018 · 39 d after period end